ONCONOVA THERAPEUTICS INC (ONTX) Stock Price, Quote, News and Overview
NASDAQ:ONTX - Nasdaq - US68232V8019 - Common Stock - Currency: USD
ONTX Quote, Performance and Key Statistics
0.9953
0 (-0.47%)
The current stock price of ONTX is 0.9953 USD. In the past month the price increased by 7.02%. In the past year, price increased by 42.19%.
ONTX Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 67.21 | 829.40B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 27.44 | 390.99B | ||
| JNJ | JOHNSON & JOHNSON | 16.25 | 390.76B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 20.56 | 230.17B | ||
| MRK | MERCK & CO. INC. | 11.71 | 226.40B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.77 | 215.98B | ||
| PFE | PFIZER INC | 8.46 | 149.04B | ||
| SNY | SANOFI-ADR | 13.58 | 136.54B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 48.97 | 113.23B | ||
| GSK | GSK PLC-SPON ADR | 7.78 | 74.77B | ||
| ZTS | ZOETIS INC | 27.1 | 72.39B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 31.95 | 44.58B |
Related stock screener links
About ONTX
Company Profile
Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the identification and development of oncology therapeutics. The company is headquartered in Newtown, Pennsylvania and currently employs 16 full-time employees. The company went IPO on 2013-07-25. The company has molecularly targeted agents designed to disrupt specific cellular pathways for cancer cell proliferation. The company has the two clinical-stage programs: narazaciclib (ON 123300), which is a multi-targeted kinase inhibitor in solid tumors and hematological malignancies as a single agent or in combination with other anti-cancer therapies; and rigosertib administered alone or in combination for the treatment of solid tumors. Narazaciclib targets cyclin-dependent kinases (CDK's), AMPK related protein kinase 5 (ARK5), and colony-stimulating factor 1 receptor (CSF1R) at low nM concentrations as well as other tyrosine kinases. The company is also engaged in supporting investigator-initiated studies (IIS) that explores the use of rigosertib for cancers driven by mutated K-Ras genes, including a Phase I/IIa study of rigosertib with a PD-1 inhibitor.
Company Info
ONCONOVA THERAPEUTICS INC
375 Pheasant Run
Newtown PENNSYLVANIA 18940 US
CEO: Steven M. Fruchtman
Employees: 16
Company Website: https://www.onconova.com/
Phone: 12677593681
ONCONOVA THERAPEUTICS INC / ONTX FAQ
What is the stock price of ONCONOVA THERAPEUTICS INC today?
The current stock price of ONTX is 0.9953 USD. The price decreased by -0.47% in the last trading session.
What is the ticker symbol for ONCONOVA THERAPEUTICS INC stock?
The exchange symbol of ONCONOVA THERAPEUTICS INC is ONTX and it is listed on the Nasdaq exchange.
On which exchange is ONTX stock listed?
ONTX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for ONCONOVA THERAPEUTICS INC stock?
9 analysts have analysed ONTX and the average price target is 8.5 USD. This implies a price increase of 754.01% is expected in the next year compared to the current price of 0.9953. Check the ONCONOVA THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ONCONOVA THERAPEUTICS INC worth?
ONCONOVA THERAPEUTICS INC (ONTX) has a market capitalization of 20.90M USD. This makes ONTX a Nano Cap stock.
How many employees does ONCONOVA THERAPEUTICS INC have?
ONCONOVA THERAPEUTICS INC (ONTX) currently has 16 employees.
What are the support and resistance levels for ONCONOVA THERAPEUTICS INC (ONTX) stock?
ONCONOVA THERAPEUTICS INC (ONTX) has a support level at 0.89 and a resistance level at 1.02. Check the full technical report for a detailed analysis of ONTX support and resistance levels.
Is ONCONOVA THERAPEUTICS INC (ONTX) expected to grow?
The Revenue of ONCONOVA THERAPEUTICS INC (ONTX) is expected to grow by 2.54% in the next year. Check the estimates tab for more information on the ONTX EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy ONCONOVA THERAPEUTICS INC (ONTX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ONTX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ONTX, evaluating the profitability, health, valuation and growth aspects
- ONCONOVA THERAPEUTICS INC (ONTX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ONCONOVA THERAPEUTICS INC (ONTX) Sales and EPS estimates to see what analysts future expectations are.
- ONCONOVA THERAPEUTICS INC (ONTX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ONCONOVA THERAPEUTICS INC (ONTX) Insider and Institutional Ownership to learn about the owners and their transactions.
- ONCONOVA THERAPEUTICS INC (ONTX) Stock Chart to make your own analysis
- ONCONOVA THERAPEUTICS INC (ONTX) Latest news and press-releases to stay up to date.
Does ONCONOVA THERAPEUTICS INC (ONTX) stock pay dividends?
ONTX does not pay a dividend.
When does ONCONOVA THERAPEUTICS INC (ONTX) report earnings?
ONCONOVA THERAPEUTICS INC (ONTX) will report earnings on 2024-05-13, after the market close.
What is the Price/Earnings (PE) ratio of ONCONOVA THERAPEUTICS INC (ONTX)?
ONCONOVA THERAPEUTICS INC (ONTX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.97).
ONTX Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to ONTX. When comparing the yearly performance of all stocks, ONTX is one of the better performing stocks in the market, outperforming 91.64% of all stocks.
ONTX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ONTX. The financial health of ONTX is average, but there are quite some concerns on its profitability.
ONTX Financial Highlights
Over the last trailing twelve months ONTX reported a non-GAAP Earnings per Share(EPS) of -0.97. The EPS decreased by -21.25% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -74.67% | ||
| ROE | -139.07% | ||
| Debt/Equity | 0 |
ONTX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 84% to ONTX. The Buy consensus is the average rating of analysts ratings from 9 analysts.
For the next year, analysts expect an EPS growth of -7.23% and a revenue growth 2.54% for ONTX